Skip to Content
Merck
  • Intraosseous infusion is unreliable for adenosine delivery in the treatment of supraventricular tachycardia.

Intraosseous infusion is unreliable for adenosine delivery in the treatment of supraventricular tachycardia.

Pediatric emergency care (2012-01-06)
Ian Scott Goodman, Christina Jennifer Lu
ABSTRACT

Supraventricular tachycardia (SVT) is a common tachyarrhythmia in the pediatric population that can necessitate immediate treatment. Adenosine has been well studied as a mainstay treatment, but the methods of adenosine administration have not been very well delineated. The intraosseous technique has presented itself as a possible method of administration. We describe 2 cases in which adenosine was administered through bone marrow infusion to convert SVT without success. The cases we describe show that intraosseous is not a reliable method of administering adenosine to stop SVT. Both patients presented with SVT refractory to vagal maneuvers and difficult intravenous placement. Intraosseous access was achieved, but administration of adenosine at increasing doses was unable to successfully convert the arrhythmia.

MATERIALS
Product Number
Brand
Product Description

Supelco
Procainamide hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
(±)-Sotalol hydrochloride, ≥98% (TLC), powder